Search

Purpose: To compare self-rated health among the United States general population in 2002 and 2017.Methods: Secondary data were analyzed from two EQ-5D valuation studies conducted in 2002 and 2017. Both studies included the EQ-5D-3L self-classifier and visual analog scale (VAS), where health is rated from 0 (worst imaginable health) to 100 (best imaginable health). VAS scores were compared between time points using regression models, adjusting for sociodemographic factors (Model 1), plus illness (Model 2), and health problems according to the EQ-5D classifier (Model 3).Results: Mean VAS scores in 2002 [84.4 (SD = 16.1)] were not different from 2017 [84.6 (SD = 14.5)] (p = 0.63), nor different after adjusting for demographics (Model 1) or illness (Model 2). However, 2017 VAS mean scores were significantly higher than 2002 [2.2 (95% CI 1.36-3.10)] upon adjusting for the presence of dimension-specific health problems.Conclusions: Self-rated health of the general US adult population in 2017 was similar to 2002, but after adjusting for health problems, scores were slightly higher in 2017. Sociodemographic shifts in age and education explain some of the differences in scores, and by removing health and sociodemographic factors, we found the VAS reveals self-rated health is slightly better in 2017 than 2002. [ABSTRACT FROM AUTHOR]

Purpose. An overview of the emerging field of comparative effectiveness research (CER) and its relevance to pharmacists and pharmacy-based decision-makers is provided. Summary. The U.S. government is investing over $1 billion on CER over the next two years. This investment is in part driven by the recognition that, despite having the highest per capita health care expenditures in the world, the United States does not always perform well on measures of health compared with other countries. There also is increased awareness of the limited information provided by results of traditional randomized clinical trials to inform decisions about therapeutic alternatives as applied in actual practice. Comparative effectiveness studies have two important principal components: (1) the comparison of two or more agents or interventions that are considered true therapeutic alternatives and (2) the examination of effects (outcomes) in actual practice. Comparative effectiveness studies differ from traditional efficacy studies in several ways, including the research question addressed, comparison groups, patient population, setting, outcomes measured, and validity. Studies that are within the scope of CER can be categorized as primary comparative effectiveness studies or secondary comparative effectiveness studies. CER also can be used to compare medical devices, procedures, health services, or any competing intervention. Conclusion. Comparative effectiveness is an emerging area of research relevant to many areas of health care, especially pharmacotherapy. The knowledge gained from CER is important to pharmacists when applying drug information and making decisions related to drug therapy. [ABSTRACT FROM AUTHOR]

Objective: To describe community pharmacists' experiences with consumer demand for imported pharmaceuticals and their opinions about economic, policy, and patient care issues surrounding importation of medications and their willingness to procure these products from international sources, if legally permitted.Design: Cross-sectional study.Setting: Four states in the United States (Michigan, Minnesota, Illinois, and Florida).Participants: Community/outpatient pharmacists.Interventions: Telephone-based survey conducted in March 2004.Main Outcome Measures: Self-reported opinions of pharmacists on importation of prescription drugs.Results: Of 401 respondents, approximately 90% agreed that the Medicare prescription drug benefit would not diminish consumer interest in importation of medications, and a similar proportion agreed that interest was not limited to the elderly. A majority of pharmacists (69%) agreed that their primary concern about importation was the quality (i.e., purity) of the drugs. However, 57% of pharmacists agreed that drugs purchased through Canada would not pose a greater risk of medication-related problems if U.S. pharmacists oversaw the process and were available to provide patient monitoring and education. Pharmacists strongly favored regulatory actions that might decrease counterfeiting. Nearly one third (32%) of pharmacists believed that consumers should be allowed to purchase medications from Canada legally, while 44% of pharmacists believed that pharmacies should be able to procure prescription drugs from Canada legally. Almost 70% of pharmacists said that they would consider ordering medications from Canada, if legally permitted. Approximately one half of the pharmacists surveyed were concerned about job security as a result of the trend toward importation. This concern was significantly higher among pharmacy owners (chi-square [df= 1] = 9.82; P < .01).Conclusion: Pharmacists expressed concern about safety, liability, and the economic ramifications of prescription drug importation. More favorable opinions were expressed for situations in which imported drugs would be channeled through U.S. pharmacies. [ABSTRACT FROM AUTHOR]